Related Experiment Video
Updated: Aug 15, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Management of molecular-targeted therapy for chronic myelogenous leukemia
Patricia Ault1, Suzan Kaled, Mary Beth Rios
1Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA. Pault@mdanderson.org
Purpose:
To provide primary care providers with guidelines on the evaluation and management of treatment for patients with chronic myelogenous leukemia (CML) with emphasis on the molecular-targeted therapy imatinib mesylate.
Data Sources:
Research-based articles in the medical literature, review articles, and clinical practice guidelines.
Conclusions:
CML is a clonal stem cell disorder causing 5,000 new cases annually. Research on molecular-targeted therapy confirms that specific protein kinases have broad consequences for the development of future drugs to treat CML. The most recent discovery is a new compound, imatinib mesylate, which has become commercially available. Currently, the standard of care for CML is this agent. This therapy has changed management strategies for treatment of patients with the diagnosis of CML.
Implications For Practice:
Long-term observations and evaluations are needed for final determination of treatment effectiveness; thus, primary care providers will follow patients with CML in the community. Unforeseen toxicity may surface, requiring accurate assessment and evaluation. Primary care providers will be actively involved with providing symptom management for these patients.
Insights
Primary care providers can now manage chronic myelogenous leukemia (CML) using imatinib mesylate, a targeted therapy. This guideline aids in evaluating and treating CML patients, improving outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myelogenous leukemia (CML) is a stem cell disorder with 5,000 new cases annually.
- Advances in molecular targeted therapy have identified specific protein kinases crucial for CML drug development.
Purpose of the Study:
- To equip primary care providers with guidelines for evaluating and managing chronic myelogenous leukemia (CML).
- Emphasis on the use of imatinib mesylate, a molecular-targeted therapy for CML treatment.
Main Methods:
- Review of research-based articles in medical literature.
- Inclusion of review articles and clinical practice guidelines.
Main Results:
- Imatinib mesylate is a newly available compound and the current standard of care for CML.
- This targeted therapy has significantly altered CML management strategies.
Conclusions:
- Primary care providers will play a key role in long-term patient follow-up and symptom management.
- Ongoing evaluation is necessary to determine the long-term effectiveness and potential toxicities of imatinib mesylate.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase